FYI:
http://www.medscape.com/viewarticle/750610
>> The latest troubles involve the company's chief executive officer, Mitchell Gold, and other company executives; they are being sued for stock fraud. Members of the management team sold $87 million of stock in the months before reporting disappointing Provenge sales figures, according a report from BNET, the CBS Interactive Business Network.
>> At the root of all these problems is the disappointing clinical uptake of the Provenge. Clinicians are reportedly concerned about being reimbursed by Medicare for the treatment, which costs $93,000 per patient.
Best to all,
- MichGuy